 NEW YORK and FORT MYERS, Fla., March 16, 2021 PRNewswire -- Elevation Oncology , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, Inc. NASDAQ:NEO, a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today a collaboration to enhance identification of patients with any solid tumor harboring an NRG1 fusion who may be eligible for enrollment in the Phase 2 CRESTONE study. 